We are pleased to invite you to join an upcoming webinar on the PsyPal project, which is investigating psychedelic therapy to address psychological distress needs in palliative care, including in neurological conditions.
PAREA is co-organising this online session with the European Commission’s EU Health Policy Platform on 13 April 2026 from 14:00 to 15:30 CEST.
People living with progressive, life limiting conditions often face severe psychological and existential distress. Many health systems still lack effective ways to address these needs.The EU funded PsyPal project is a clinical trial examining whether psilocybin-assisted therapy can reduce depressive symptoms in people living with several progressive, incurable conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), atypical Parkinsonian disorders, and other severe neurodegenerative diseases.
The PsyPal therapy model combines preparation, therapeutic intervention, and integration with psychotherapeutic support.
The webinar will discuss palliative care needs, emerging scientific evidence, ethical considerations in trials, and the regulatory landscape for psychedelic therapies in Europe.
Speakers include:
• Dr Cathy Payne, European Association for Palliative Care (EAPC)
• Dr Simone Veronese, Vice President, EAPC (video recording)
• Prof. Robert Schoevers, University Medical Center Groningen
• Ian Roullier, Psychedelic Participant Advocacy Network (PsyPAN)
• Tadeusz Hawrot, Founder and Executive Director, PAREA
